Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study
- PMID: 34016619
- PMCID: PMC8135927
- DOI: 10.1183/13993003.04474-2020
Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study
Abstract
Background: Influenza epidemics were initially considered to be a suitable model for the COVID-19 epidemic, but there is a lack of data concerning patients with chronic respiratory diseases (CRDs), who were supposed to be at risk of severe forms of COVID-19.
Methods: This nationwide retrospective cohort study describes patients with prior lung disease hospitalised for COVID-19 (March-April 2020) or influenza (2018-2019 influenza outbreak). We compared the resulting pulmonary complications, need for intensive care and in-hospital mortality depending on respiratory history and virus.
Results: In the 89 530 COVID-19 cases, 16.03% had at least one CRD, which was significantly less frequently than in the 45 819 seasonal influenza patients. Patients suffering from chronic respiratory failure, chronic obstructive pulmonary disease, asthma, cystic fibrosis and pulmonary hypertension were under-represented, contrary to those with lung cancer, sleep apnoea, emphysema and interstitial lung diseases. COVID-19 patients with CRDs developed significantly more ventilator-associated pneumonia and pulmonary embolism than influenza patients. They needed intensive care significantly more often and had a higher mortality rate (except for asthma) when compared with patients with COVID-19 but without CRDs or patients with influenza.
Conclusions: Patients with prior respiratory diseases were globally less likely to be hospitalised for COVID-19 than for influenza, but were at higher risk of developing severe COVID-19 and had a higher mortality rate compared with influenza patients and patients without a history of respiratory illness.
Copyright ©The authors 2021.
Conflict of interest statement
Conflict of interest: G. Beltramo has nothing to disclose. Conflict of interest: J. Cottenet has nothing to disclose. Conflict of interest: A-S. Mariet has nothing to disclose. Conflict of interest: M. Georges has nothing to disclose. Conflict of interest: L. Piroth has nothing to disclose. Conflict of interest: P. Tubert-Bitter has nothing to disclose. Conflict of interest: P. Bonniaud reports personal fees for advisory board work and other (travel expenses reimbursement) from Roche, personal fees for advisory board work and other (meeting attendance/registration) from Boehringer and Novartis, personal fees for advisory board work from Teva and AstraZeneca, other (travel expenses reimbursement) from Chiesi, other (meeting attendance/registration) from Stallergene, other (meeting attendance/registration and travel expenses reimbursement) from Sanofi, outside the submitted work. Conflict of interest: C. Quantin has nothing to disclose.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous